SI3626729T1 - Novi peptidi in kombinacija peptidov za uporabo v imunoterapiji proti hepatocelularnem karcinomu (HCC) in drugim oblikam raka - Google Patents

Novi peptidi in kombinacija peptidov za uporabo v imunoterapiji proti hepatocelularnem karcinomu (HCC) in drugim oblikam raka

Info

Publication number
SI3626729T1
SI3626729T1 SI201531721T SI201531721T SI3626729T1 SI 3626729 T1 SI3626729 T1 SI 3626729T1 SI 201531721 T SI201531721 T SI 201531721T SI 201531721 T SI201531721 T SI 201531721T SI 3626729 T1 SI3626729 T1 SI 3626729T1
Authority
SI
Slovenia
Prior art keywords
peptides
hcc
cancers
combination
hepatocellular carcinoma
Prior art date
Application number
SI201531721T
Other languages
English (en)
Slovenian (sl)
Inventor
Toni Weinschenk
Andrea Mahr
Jens Fritsche
Phillip Muller
Anita Wiebe
Sarah Missel
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52630910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3626729(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of SI3626729T1 publication Critical patent/SI3626729T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
SI201531721T 2014-12-23 2015-12-16 Novi peptidi in kombinacija peptidov za uporabo v imunoterapiji proti hepatocelularnem karcinomu (HCC) in drugim oblikam raka SI3626729T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462096165P 2014-12-23 2014-12-23
GB201423016 2014-12-23
GBGB1501017.6A GB201501017D0 (en) 2014-12-23 2015-01-21 Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
EP19199101.7A EP3626729B1 (en) 2014-12-23 2015-12-16 Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers

Publications (1)

Publication Number Publication Date
SI3626729T1 true SI3626729T1 (sl) 2021-11-30

Family

ID=52630910

Family Applications (3)

Application Number Title Priority Date Filing Date
SI201531682T SI3545965T1 (sl) 2014-12-23 2015-12-16 Novi peptidi in kombinacija peptidov za uporabo v imunoterapiji proti hepatocelularnem karcinomu (HCC)in drugim oblikam raka
SI201531025T SI3236985T2 (sl) 2014-12-23 2015-12-16 Novi peptidi in kombinacija peptidov za uporabo v imunoterapiji proti hepatocelularnem karcinomu (HCC) in drugim oblikam raka
SI201531721T SI3626729T1 (sl) 2014-12-23 2015-12-16 Novi peptidi in kombinacija peptidov za uporabo v imunoterapiji proti hepatocelularnem karcinomu (HCC) in drugim oblikam raka

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI201531682T SI3545965T1 (sl) 2014-12-23 2015-12-16 Novi peptidi in kombinacija peptidov za uporabo v imunoterapiji proti hepatocelularnem karcinomu (HCC)in drugim oblikam raka
SI201531025T SI3236985T2 (sl) 2014-12-23 2015-12-16 Novi peptidi in kombinacija peptidov za uporabo v imunoterapiji proti hepatocelularnem karcinomu (HCC) in drugim oblikam raka

Country Status (25)

Country Link
US (8) US10064926B2 (enExample)
EP (8) EP3626730A1 (enExample)
JP (2) JP6906156B2 (enExample)
KR (1) KR102284493B1 (enExample)
CN (4) CN107001414A (enExample)
AR (2) AR103220A1 (enExample)
AU (3) AU2015371490B2 (enExample)
BR (1) BR112017008972A2 (enExample)
CA (1) CA2972126A1 (enExample)
CL (1) CL2017001391A1 (enExample)
CR (1) CR20170282A (enExample)
DK (4) DK3626729T3 (enExample)
EA (2) EA202190587A3 (enExample)
GB (1) GB201501017D0 (enExample)
IL (1) IL250989B (enExample)
MA (3) MA40136A1 (enExample)
MX (1) MX377144B (enExample)
PE (1) PE20170940A1 (enExample)
PH (1) PH12017500484B1 (enExample)
PL (1) PL3236985T5 (enExample)
RS (4) RS62508B1 (enExample)
SG (1) SG11201703322UA (enExample)
SI (3) SI3545965T1 (enExample)
TW (1) TWI687436B (enExample)
WO (1) WO2016102272A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
US10813984B2 (en) * 2014-04-24 2020-10-27 Rhode Island Hospital Aspartate-β-hydroxylase induces epitope-specific T cell responses in tumors
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
UA120945C2 (uk) 2014-12-23 2020-03-10 Новартіс Аг Сполуки триазолопіримідину та їх застосування
EP4461371A3 (en) 2014-12-23 2025-02-26 immatics biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
MY198087A (en) 2015-10-05 2023-07-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
AU2016369519B2 (en) 2015-12-16 2023-04-20 Seattle Project Corp. Neoantigen identification, manufacture, and use
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
CN109906224B (zh) 2016-06-20 2022-02-25 诺华股份有限公司 三唑吡啶化合物及其应用
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
EP3472168B1 (en) 2016-06-20 2024-01-10 Novartis AG Crystalline forms of triazolopyrimidine compound
EP4406613A3 (en) * 2016-10-07 2024-10-23 IO Biotech ApS Immunogenic arginase peptides
CN110494543A (zh) 2016-10-19 2019-11-22 弗洛设计声能学公司 通过声学的亲和细胞提取
NZ754222A (en) 2016-12-08 2022-02-25 Immatics Biotechnologies Gmbh T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4035675A3 (en) * 2017-01-27 2022-11-16 Immatics Biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
JP2020523022A (ja) 2017-06-14 2020-08-06 アイカーン スクール オブ メディシン アット マウント サイナイ 免疫療法に反応する肝細胞癌のクラスの検出および治療方法
DE102017115966A1 (de) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptidmolekül mit verbesserter zweifacher Spezifität
RS61817B1 (sr) 2017-07-14 2021-06-30 Immatics Biotechnologies Gmbh Poboljšani polipeptidni molekul sa dvojnom specifičnošću
US11802315B2 (en) * 2017-08-09 2023-10-31 Pamgene B.V. Method for predicting the response of non-small-cell lung carcinoma patients to a medicament
GB201713700D0 (en) * 2017-08-25 2017-10-11 Anastasis Biotec Ltd Peptide conjugates
CA3078744A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. Neoantigen identification using hotspots
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
JP2021507561A (ja) 2017-12-14 2021-02-22 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． 音響トランスデューサドライバ及びコントローラ
US12357694B2 (en) 2018-03-12 2025-07-15 The Children's Hospital Of Philadelphia Methods and compositions for use of tumor self-antigens in adoptive immunotherapy
WO2019237101A1 (en) 2018-06-08 2019-12-12 The Board Of Regents Of The University Of Oklahoma Peptide therapeutics for treating alzheimer's disease and related conditions
DE102018122546B3 (de) * 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden
GB201815549D0 (en) 2018-09-24 2018-11-07 Io Biotech Aps Arginase1 polypeptides
WO2020084621A1 (en) * 2018-10-26 2020-04-30 Tami Bar Compositions and methods for biodegrading alcohol
CN109663128A (zh) * 2018-11-21 2019-04-23 中国农业大学 一种肺动脉高压标志物及其作为治疗靶点的应用
JP2022512384A (ja) * 2018-12-13 2022-02-03 ロード アイランド ホスピタル Ａｓｐｈ発現腫瘍の成長および進行の阻害
EP3721899A1 (en) 2019-04-08 2020-10-14 China Medical University Combination therapies comprising dendritic cells-based vaccine and immune checkpoint inhibitor
CN110850086B (zh) * 2019-11-18 2023-05-02 西安交通大学 一种肝移植术后缺血性胆道病变血清诊断标志物acly的应用
CN113461799A (zh) * 2020-03-18 2021-10-01 北京鼎成肽源生物技术有限公司 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用
JP7503864B2 (ja) * 2020-03-30 2024-06-21 ロペルバイオ カンパニー リミテッド 免疫抗がん療法に対するバイオマーカーおよびその用途
CA3183756A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
CN116333984A (zh) * 2020-07-14 2023-06-27 广州泛恩生物科技有限公司 基于galnt2阳性t细胞的用于杀伤肿瘤的tcr-t细胞及其制备方法和应用
CN112063718A (zh) * 2020-09-18 2020-12-11 中国医科大学 Usp14在肝细胞肝癌诊断、预后判断以及治疗中的应用
CN112043722B (zh) * 2020-09-25 2022-02-15 中国医科大学 Prpf6在前列腺癌及去势抵抗前列腺癌治疗中的应用
CN114574486B (zh) * 2020-12-01 2024-04-16 中国科学院大连化学物理研究所 作用于OPLAH的siRNA、DNA及构建物和应用
CN114163512B (zh) * 2021-03-24 2025-02-25 深圳市新靶向生物科技有限公司 一种与肝癌驱动基因突变相关的抗原肽组合及其应用
TW202313681A (zh) 2021-04-02 2023-04-01 美商安進公司 Ｍａｇｅｂ２結合構建體
JP2024529907A (ja) * 2021-07-19 2024-08-14 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Ｔ細胞機能の疲弊を処置し、がん免疫療法を強化するためのｍｃｔ１１抗体
CN115634281B (zh) * 2021-07-20 2025-12-02 肖伯端 Ctrp3蛋白的抗瘤作用及编码其的重组溶瘤病毒及制备方法和应用
CN113502300B (zh) * 2021-07-21 2024-02-06 徐州医科大学 一种含有hdac10基因启动子序列和报告基因的重组质粒、制备方法及应用
US20250289866A1 (en) * 2021-10-18 2025-09-18 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use
CN115572764B (zh) * 2022-03-30 2024-06-21 江苏鹍远生物技术有限公司 一组肿瘤检测标志物及其用途
CN116334031A (zh) * 2022-07-21 2023-06-27 中国人民解放军陆军军医大学 三个多肽及其在制备ⅰ型糖尿病免疫防治疫苗或药物中的应用
CN116042825B (zh) * 2022-09-28 2025-07-01 南方医科大学 一种评估5-fu治疗胃癌癌敏感性的探针引物组及其试剂盒
WO2024235848A1 (en) * 2023-05-12 2024-11-21 Fundación Para La Investigación Médica Aplicada Novel t cell receptors
WO2025021979A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
WO2025021968A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Antigen binding proteins against mageb2
CN119524137A (zh) * 2024-12-11 2025-02-28 徐州医科大学 Fbxo22在诊断、治疗非酒精性脂肪性肝病中的应用

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
DD147855A5 (de) 1978-12-22 1981-04-22 Biogen Nv Verfahren zur erzeugung mindestens eines hbv-antigenwirkung aufweisenden polypeptids
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
FI955798L (fi) 1993-06-03 1996-02-01 Therapeutic Antibodies Inc Terapeuttiset vasta-ainefrangmentit
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
AU1394497A (en) 1996-01-17 1997-08-11 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20020061552A1 (en) * 1999-12-17 2002-05-23 Dong Yan Mammalian dishevelled-associated proteins
WO2001062908A2 (en) 2000-02-22 2001-08-30 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP2316950A1 (en) 2000-03-27 2011-05-04 Technion Research and Development Foundation, Ltd. Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
AU7524601A (en) 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
WO2002007783A2 (en) 2000-07-20 2002-01-31 Regents Of The University Of Minnesota Radiolabeled immunotoxins
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US20050053918A1 (en) 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
US7311914B2 (en) 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
WO2004018667A1 (ja) * 2002-08-26 2004-03-04 Kirin Beer Kabushiki Kaisha ペプチド及びこれを含む医薬
EP1549748B1 (en) 2002-10-09 2014-10-01 Immunocore Ltd. Single chain recombinant t cell receptors
WO2004044004A2 (en) 2002-11-09 2004-05-27 Avidex Limited T cell receptor display
US20040096982A1 (en) 2002-11-19 2004-05-20 International Business Machines Corporation Methods and apparatus for analysis of mass spectra
SI1581812T1 (sl) * 2003-01-06 2008-10-31 Wyeth Corp Sestavki in postopki za diagnosticiranje in zdravljenje raka kolona
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US20090075304A1 (en) 2004-05-27 2009-03-19 Weidanz Jon A Methods of assaying vaccine potency
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090233318A1 (en) 2004-12-28 2009-09-17 Weidanz Jon A Methods of assaying vaccine potency
ES2330013T3 (es) 2005-09-05 2009-12-03 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii y vacunas contra el cancer relacionadas.
SI1806359T1 (sl) 2005-09-05 2010-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi ki se vežejo brez izjeme na molekule humanega levkocitnega antigena HLA razred II
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
DK2183361T3 (en) * 2007-07-27 2015-07-27 Immatics Biotechnologies Gmbh Novel immunotherapy against brain tumors
UA103882C2 (uk) * 2007-07-27 2013-12-10 Імматікс Біотекнолоджіс Гмбх Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина
WO2009026547A1 (en) 2007-08-22 2009-02-26 Receptor Logi, Ltd. Methods of assaying vaccine potency
HUE029164T2 (hu) * 2007-09-14 2017-02-28 Univ Brussel Vrije Humán antigén-prezentáló sejtek T-sejteket stimuláló képességének fokozása és azok alkalmazása vakcinázásra
EP2262834A4 (en) 2008-02-27 2011-08-17 Receptor Logic Inc ANTIBODIES AS T-CELL RECEPTOR MIMETICS, MANUFACTURING METHOD AND ITS USES
ME02267B (me) * 2008-03-27 2016-04-28 Immatics Biotechnologies Gmbh Nova imunoterapija protiv tumora nervnih ćelija i mozga
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
WO2009151487A1 (en) 2008-06-13 2009-12-17 Receptor Logic, Inc. Methods of assaying vaccine potency
DE102008049136B4 (de) 2008-09-26 2012-10-25 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Neue Regulatoren des angeborenen Immunsystems
PT2172211E (pt) * 2008-10-01 2015-03-09 Immatics Biotechnologies Gmbh Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
US9125850B2 (en) 2009-11-14 2015-09-08 Cardio Vax, Llc Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
US8506964B2 (en) 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2632955A1 (en) 2010-10-26 2013-09-04 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2012065133A1 (en) 2010-11-12 2012-05-18 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of aneurysms
AU2011336997A1 (en) 2010-11-12 2013-05-30 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
EP2637686A2 (en) 2010-11-12 2013-09-18 Cedars-Sinai Medical Center Immunomodulatory compositions, methods and systems comprising immunogenic fragments of apob100
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
WO2013070603A1 (en) * 2011-11-11 2013-05-16 Cedars-Sinai Medical Center Compositions and methods for treatment of kidney diseases
GB201208293D0 (en) * 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
EP2892544A4 (en) * 2012-09-05 2016-11-02 Univ Virginia Patent Found TARGET PEPTIDES FOR THERAPY AND DIAGNOSIS OF COLORECTAL CARCINOMAS
ES2603589T3 (es) 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
US9134326B2 (en) * 2013-03-14 2015-09-15 Battelle Memorial Institute Biomarkers for liver fibrosis
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
CN103739667B (zh) * 2013-09-24 2017-08-25 上海宇研生物技术有限公司 卵巢癌特异的肿瘤抗原肽及其制备方法
JP2017511151A (ja) 2014-03-14 2017-04-20 イムノコア リミテッド Ｔｃｒライブラリ
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
US20180179283A1 (en) 2015-06-08 2018-06-28 Adicet Bio Inc. T cell receptor like antibodies having fine specificity
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
ES2891321T3 (es) 2016-04-08 2022-01-27 Adaptimmune Ltd Receptores de células T
DK3440102T3 (da) 2016-04-08 2024-07-22 Adaptimmune Ltd T-cellereceptorer
ES2788188T5 (es) 2016-04-08 2023-10-24 Adaptimmune Ltd Receptores de linfocitos T
AU2017302541B2 (en) 2016-07-27 2021-08-12 Sharp Kabushiki Kaisha Wireless telecommunications methods and apparatus using system information value tag
US20200325244A1 (en) 2020-05-18 2020-10-15 Abexxa Biologics, Inc. Antibodies and methods of use thereof
CN110809580A (zh) 2017-01-24 2020-02-18 安贝科思生物制剂公司 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物
EP3636761B1 (en) 2017-06-05 2024-07-31 Mie University Antigen-binding protein recognizing mage-a4-derived peptide
JP7722629B2 (ja) 2017-07-04 2025-08-13 キュアバック エスイー 新規核酸分子
EP3668539A4 (en) 2017-08-18 2021-08-18 Gritstone Oncology, Inc. ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS
CN111315769A (zh) 2017-09-06 2020-06-19 加州理工学院 信号传导和抗原呈递双功能受体(sabr)
AU2018395397A1 (en) 2017-12-28 2020-08-06 Gritstone Bio, Inc. Antigen-binding proteins targeting shared antigens
CN112236447B (zh) 2018-04-19 2023-10-20 得克萨斯州大学系统董事会 具有mage-b2特异性的t细胞受体及其用途
WO2019226941A1 (en) 2018-05-23 2019-11-28 Gritstone Oncology, Inc. Shared antigens
US20200291128A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US20200291116A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US20200291127A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof

Also Published As

Publication number Publication date
MA41237B1 (fr) 2019-12-31
RS62448B1 (sr) 2021-11-30
GB201501017D0 (en) 2015-03-04
RS62508B1 (sr) 2021-11-30
EP3545965A3 (en) 2019-12-25
EP3626729B1 (en) 2021-09-08
MA49158B1 (fr) 2021-12-31
EP3236985B2 (en) 2022-09-07
CN112646025A (zh) 2021-04-13
US11786583B2 (en) 2023-10-17
DK3626731T3 (da) 2021-11-22
EP3620168A1 (en) 2020-03-11
EP3626731A1 (en) 2020-03-25
EA202190587A2 (ru) 2021-06-30
EP3236985B1 (en) 2019-09-25
EP3236985A1 (en) 2017-11-01
AU2015371490A1 (en) 2017-03-23
AU2015371490B2 (en) 2020-08-13
RS59836B1 (sr) 2020-02-28
EA201791150A1 (ru) 2018-03-30
BR112017008972A2 (pt) 2018-01-16
US20210268089A1 (en) 2021-09-02
MX2017008329A (es) 2017-10-26
AR122964A2 (es) 2022-10-19
SI3236985T1 (sl) 2020-01-31
CR20170282A (es) 2018-01-29
US20190000947A1 (en) 2019-01-03
MA40136A1 (fr) 2018-05-31
PL3236985T4 (pl) 2020-12-14
CN112538109A (zh) 2021-03-23
CN112646021A (zh) 2021-04-13
PH12017500484A1 (en) 2017-08-07
WO2016102272A1 (en) 2016-06-30
DK3626729T3 (da) 2021-11-01
EP3626730A1 (en) 2020-03-25
US20180207252A1 (en) 2018-07-26
US11406693B2 (en) 2022-08-09
MX377144B (es) 2025-03-07
MA49158A (fr) 2020-03-25
EP3545965B1 (en) 2021-07-21
TW201629096A (zh) 2016-08-16
EP3616706A1 (en) 2020-03-04
US20200376103A1 (en) 2020-12-03
EP3545965A2 (en) 2019-10-02
AU2020213295B2 (en) 2022-09-01
PL3236985T5 (pl) 2023-03-06
US20200405831A1 (en) 2020-12-31
AU2020213294A1 (en) 2020-09-03
SI3236985T2 (sl) 2023-01-31
RS59836B2 (sr) 2023-01-31
IL250989B (en) 2021-04-29
EP3715357B1 (en) 2024-11-06
JP7713309B2 (ja) 2025-07-25
SI3545965T1 (sl) 2021-11-30
AR103220A1 (es) 2017-04-26
TWI687436B (zh) 2020-03-11
US20170080070A1 (en) 2017-03-23
PE20170940A1 (es) 2017-07-13
SG11201703322UA (en) 2017-07-28
KR102284493B1 (ko) 2021-08-02
PL3236985T3 (pl) 2020-04-30
JP2021104033A (ja) 2021-07-26
JP6906156B2 (ja) 2021-07-21
CN107001414A (zh) 2017-08-01
EP3626729A1 (en) 2020-03-25
CA2972126A1 (en) 2016-06-30
AU2020213294B2 (en) 2022-10-06
JP2018509135A (ja) 2018-04-05
US10064926B2 (en) 2018-09-04
PH12017500484B1 (en) 2024-01-05
US20160250307A1 (en) 2016-09-01
EA202190587A3 (ru) 2021-09-30
DK3545965T3 (da) 2021-09-13
MA41237A (fr) 2017-11-01
CL2017001391A1 (es) 2017-12-29
IL250989A0 (en) 2017-04-30
US20180207253A1 (en) 2018-07-26
KR20170090447A (ko) 2017-08-07
EP3626731B1 (en) 2021-09-08
AU2020213295A1 (en) 2020-09-03
DK3616706T3 (da) 2021-11-15
EP3616706B1 (en) 2021-10-13
RS62237B1 (sr) 2021-09-30
EP3715357A1 (en) 2020-09-30

Similar Documents

Publication Publication Date Title
IL250989B (en) New peptides and a combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other types of cancer
SG10202101368WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
IL256189A (en) New peptides and combinations of peptides used in immunotherapy against ovarian cancer and other types of cancer
IL258599A (en) New peptides and a combination of peptides used in immunotherapy against breast cancer and other types of cancer
SG10202001485UA (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
SG10202110292UA (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers
GB201511792D0 (en) Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
SG10202001665QA (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
LT3394084T (lt) Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš krūties ir kitų tipų vėžį
GB201604458D0 (en) Peptides and combination of peptides for use in immunotherapy against cancers
GB201604490D0 (en) Peptides combination of peptides for use in immunotherapy against cancers
IL258609A (en) New peptides and a combination of peptides for use in immunotherapy against several types of cancer
IL281752A (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
ZA201805512B (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers